HUTCHMED (China) (HMDCF) Receivables - Other (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Receivables - Other came in at $44.0 million in Q2 2026, down 13.11% year-over-year from $50.7 million in Q2 2025, and down 15.01% quarter-over-quarter from $51.8 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Receivables - Other (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Receivables - Other for 12 consecutive years, with $44.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables - Other fell 13.11% year-over-year to $44.0 million in Q2 2026; TTM through Jun 2026 was $44.0 million, a 13.11% decrease from a year earlier, with the FY2025 full-year figure at $51.8 million, changed N/A from the prior year.
- Receivables - Other was $44.0 million for Q2 2026 at HUTCHMED (China), down from $51.8 million in the prior quarter.
- Over five years, Receivables - Other peaked at $51.8 million in Q4 2025 and troughed at -$339000.0 in Q4 2023.
- A 5-year average of $24.7 million and a median of $24.8 million in 2023 frame the typical range for Receivables - Other.
- The widest YoY moves for Receivables - Other: up 1113.2% in 2023, down 326.0% in 2023.
- Over 5 years, Receivables - Other stood at $150000.0 in 2022, then plunged by 326.0% to -$339000.0 in 2023, then surged by 8281.71% to $27.7 million in 2024, then surged by 86.75% to $51.8 million in 2025, then fell by 15.01% to $44.0 million in 2026.
- The last three Receivables - Other figures came in at $44.0 million (Q2 2026), $51.8 million (Q4 2025), and $50.7 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.02 Mn |
| Dec 31, 2025 | 51.80 Mn |
| Jun 30, 2025 | 50.66 Mn |
| Jun 30, 2024 | 27.74 Mn |
| Dec 31, 2023 | -339,000.00 |
| Jun 30, 2023 | 21.96 Mn |
| Dec 31, 2022 | 150,000.00 |
| Jun 30, 2022 | 1.81 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Jun 30, 2021 | 24.23 Mn |
| Dec 31, 2020 | 2.96 Mn |
| Jun 30, 2020 | 15.25 Mn |
| Dec 31, 2019 | 39.67 Mn |
| Sep 30, 2019 | 4.19 Mn |
| Jun 30, 2019 | 1.79 Mn |
| Mar 31, 2019 | 2.19 Mn |
| Dec 31, 2018 | 27,000.00 |
| Jun 30, 2018 | 2.55 Mn |
| Dec 31, 2017 | 220,000.00 |
| Jun 30, 2017 | 2.42 Mn |